Stock CODX CO-DIAGNOSTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Co-Diagnostics, Inc.

Equities

CODX

US1897631057

Market Closed - Nasdaq
Other stock markets
 02:00:00 04/05/2024 am IST 		5-day change 1st Jan Change
1.21 USD +0.83% Intraday chart for Co-Diagnostics, Inc. +9.01% -9.02%
12/04 Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event CI
04/04 Co-Diagnostics, Inc. Appoints Executive Appointments CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event
Co-Diagnostics, Inc. Appoints Executive Appointments
Co-Diagnostics, Inc. Appoints Richard Abbott as President
Co-Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Co-Diagnostics Gets Approval From India's Central Drugs Standard Control Organization For Manufacturing, Sale of Influenza Multiplex Test
Co-Diagnostics Submits PCR COVID-19 Test and PCR Pro Instrument for FDA Review
Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro
Co-Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer
Co-Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Co-Diagnostics Wins Gates Foundation Grants for Tuberculosis, HPV Tests
Co-Diagnostics, Inc. Announces Recent Grant Awards
Co-Diagnostics Receives $1.2 Million in New Funds From National Institutes of Health
Co-Diagnostics, Inc. Receives Funding for Co-Dx PCR Home Platform from NIH RADx Tech Program
Co-Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Sector Update: Health Care Stocks Slip Pre-Bell Friday
Co-Diagnostics Files $150 Million Mixed Shelf
Co-Diagnostics, Inc. Initiates Clinical Evaluations for At-Home and Point-of-Care Co Dx PCR Home(TM) Platform
Co-Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Earnings Reaction History: Co-Diagnostics Inc, 60.0% Follow-Through Indicator, 17.0% Sensitive
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CODX Stock
  4. News Co-Diagnostics, Inc.
  5. Other languages